Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

Evaluatie van de werkzaamheid en veiligheid van Belantamab Mafodotin, Bortezomib en Dexamethason Versus Daratumumab, Bortezomib en Dexamethason bij deelnemers met recidiverend/refractair multipel myeloom (DREAMM 7)

29 oktober 2026 bijgewerkt door: GlaxoSmithKline

DREAMM 7: Een multicenter, open-label, gerandomiseerde fase III-studie om de werkzaamheid en veiligheid van de combinatie van Belantamab Mafodotin, Bortezomib en Dexamethason (B-Vd) te evalueren in vergelijking met de combinatie van Daratumumab, Bortezomib en Dexamethason (D-Vd ) bij deelnemers met recidiverend/refractair multipel myeloom

This is a Phase 3, randomized, open-label study designed to evaluate safety and efficacy of belantamab mafodotin in combination with bortezomib/dexamethasone (Arm A) versus daratumumab in combination with bortezomib/dexamethasone (Arm B) in the participants with relapsed recurrent multiple myeloma.

Studie Overzicht

Studietype

Ingrijpend

Inschrijving (Werkelijk)

494

Fase

  • Fase 3

Uitgebreide toegang

Goedgekeurd te koop aan het publiek. Zie uitgebreid toegangsrecord.

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studie Locaties

    • New South Wales
      • Camperdown, New South Wales, Australië, 2050
        • GSK Investigational Site
      • Liverpool, New South Wales, Australië, 2170
        • GSK Investigational Site
      • Newcastle, New South Wales, Australië, 2298
        • GSK Investigational Site
      • St Leonards, New South Wales, Australië, 2065
        • GSK Investigational Site
      • Wollongong, New South Wales, Australië, 2500
        • GSK Investigational Site
    • Queensland
      • Benowa, Queensland, Australië, 4217
        • GSK Investigational Site
      • Herston, Queensland, Australië, 4029
        • GSK Investigational Site
    • South Australia
      • Ashford, South Australia, Australië, 5037
        • GSK Investigational Site
    • Victoria
      • Box Hill, Victoria, Australië, 3128
        • GSK Investigational Site
      • Heidelberg, Victoria, Australië, 3084
        • GSK Investigational Site
      • Melbourne, Victoria, Australië, 3004
        • GSK Investigational Site
    • Western Australia
      • Murdoch, Western Australia, Australië, 6150
        • GSK Investigational Site
      • Nedlands, Western Australia, Australië, 6009
        • GSK Investigational Site
      • Roeselare, België, 8800
        • GSK Investigational Site
    • Brussels Capital
      • Jette, Brussels Capital, België, 1090
        • GSK Investigational Site
      • Woluwé-Saint-Lambert, Brussels Capital, België, 1200
        • GSK Investigational Site
    • Oost-Vlaanderen
      • Ghent, Oost-Vlaanderen, België, 9000
        • GSK Investigational Site
      • Joinville, Brazilië, 89201-260
        • GSK Investigational Site
      • Natal, Brazilië, 59075-740
        • GSK Investigational Site
      • Rio de Janeiro, Brazilië, 22775001
        • GSK Investigational Site
      • São Paulo, Brazilië, 04537-080
        • GSK Investigational Site
      • São Paulo, Brazilië, 05403-000
        • GSK Investigational Site
    • Rio Grande do Sul
      • Porto Alegre, Rio Grande do Sul, Brazilië, 90035-903
        • GSK Investigational Site
    • Santa Catarina
      • Florianópolis, Santa Catarina, Brazilië, 88020-210
        • GSK Investigational Site
    • Alberta
      • Edmonton, Alberta, Canada, T6G 1Z2
        • GSK Investigational Site
    • Ontario
      • London, Ontario, Canada, N6A 5W9
        • GSK Investigational Site
      • Toronto, Ontario, Canada, M4N 3M5
        • GSK Investigational Site
    • Quebec
      • Montreal, Quebec, Canada, H4J 1C5
        • GSK Investigational Site
      • Beijing, China, 100191
        • GSK Investigational Site
      • Beijing, China, 100020
        • GSK Investigational Site
      • Changchun, China, 130012
        • GSK Investigational Site
      • Guangzhou, China, 510060
        • GSK Investigational Site
      • Guangzhou, China, 510515
        • GSK Investigational Site
      • Hangzhou, China, 310003
        • GSK Investigational Site
      • Jinan, China, 250012
        • GSK Investigational Site
      • Nanjing, China, 210008
        • GSK Investigational Site
      • Shenyang, China, 110001
        • GSK Investigational Site
      • Suzhou, China, 215006
        • GSK Investigational Site
      • Tianjin, China, 300020
        • GSK Investigational Site
      • Zhengzhou, China, 450052
        • GSK Investigational Site
      • Cologne, Duitsland, 50937
        • GSK Investigational Site
    • Baden-Wurttemberg
      • Ulm, Baden-Wurttemberg, Duitsland, 89081
        • GSK Investigational Site
    • Bavaria
      • München, Bavaria, Duitsland, 81377
        • GSK Investigational Site
      • Würzburg, Bavaria, Duitsland, 97080
        • GSK Investigational Site
    • North Rhine-Westphalia
      • Düsseldorf, North Rhine-Westphalia, Duitsland, 40225
        • GSK Investigational Site
    • Thuringia
      • Jena, Thuringia, Duitsland, 07747
        • GSK Investigational Site
      • Amiens, Frankrijk, 80054
        • GSK Investigational Site
      • Caen, Frankrijk, 14033
        • GSK Investigational Site
      • Nice, Frankrijk, 06200
        • GSK Investigational Site
      • Paris, Frankrijk, 75651
        • GSK Investigational Site
      • Rennes, Frankrijk, 35033
        • GSK Investigational Site
      • Athens, Griekenland, 11528
        • GSK Investigational Site
      • Thessaloniki, Griekenland, 54007
        • GSK Investigational Site
    • East Macedonia and Thrace
      • Alexandroupoli, East Macedonia and Thrace, Griekenland, 681 00
        • GSK Investigational Site
      • Jerusalem, Israël, 91120
        • GSK Investigational Site
      • Kfar Saba, Israël, 44281
        • GSK Investigational Site
      • Ramat Gan, Israël, 52621
        • GSK Investigational Site
      • Tel Aviv, Israël, 64239
        • GSK Investigational Site
      • Bergamo, Italië, 24127
        • GSK Investigational Site
      • Bologna, Italië, 40138
        • GSK Investigational Site
      • Brescia, Italië, 25123
        • GSK Investigational Site
      • Catania, Italië, 95123
        • GSK Investigational Site
      • Meldola FC, Italië, 47014
        • GSK Investigational Site
      • Milan, Italië, 20133
        • GSK Investigational Site
      • Ravenna, Italië, 48121
        • GSK Investigational Site
      • Roma, Italië, 00168
        • GSK Investigational Site
      • Siena, Italië, 53100
        • GSK Investigational Site
      • Torino, Italië, 10126
        • GSK Investigational Site
      • Aichi, Japan, 467-8602
        • GSK Investigational Site
      • Aichi, Japan, 441-8570
        • GSK Investigational Site
      • Aomori, Japan, 030-8553
        • GSK Investigational Site
      • Ehime, Japan, 790-8524
        • GSK Investigational Site
      • Fukuoka, Japan, 806-8501
        • GSK Investigational Site
      • Fukuoka, Japan, 807-8555
        • GSK Investigational Site
      • Fukuoka, Japan, 810-8563
        • GSK Investigational Site
      • Fukuoka, Japan, 815-8555
        • GSK Investigational Site
      • Gifu, Japan, 503-8502
        • GSK Investigational Site
      • Gunma, Japan, 377-0280
        • GSK Investigational Site
      • Hyōgo, Japan, 670-8540
        • GSK Investigational Site
      • Kanagawa, Japan, 247-8533
        • GSK Investigational Site
      • Kanagawa, Japan, 221-0855
        • GSK Investigational Site
      • Kochi, Japan, 781-8555
        • GSK Investigational Site
      • Nagano, Japan, 392-8510
        • GSK Investigational Site
      • Okayama, Japan, 701-1192
        • GSK Investigational Site
      • Osaka, Japan, 545-8586
        • GSK Investigational Site
      • Osaka, Japan, 530-0012
        • GSK Investigational Site
      • Shizuoka, Japan, 411-8777
        • GSK Investigational Site
      • Groningen, Nederland, 9713 GZ
        • GSK Investigational Site
    • South Holland
      • Dordrecht, South Holland, Nederland, 3318 AT
        • GSK Investigational Site
      • Christchurch, Nieuw-Zeeland, 8011
        • GSK Investigational Site
      • Dunedin, Nieuw-Zeeland, 9054
        • GSK Investigational Site
      • Takapuna Auckland, Nieuw-Zeeland, 1309
        • GSK Investigational Site
      • Wellington, Nieuw-Zeeland, 6021
        • GSK Investigational Site
      • Chorzów, Polen, 41-500
        • GSK Investigational Site
      • Krakow, Polen, 30510
        • GSK Investigational Site
      • Lodz, Polen, 93-513
        • GSK Investigational Site
      • Lublin, Polen, 20-081
        • GSK Investigational Site
      • Lublin, Polen, 20-090
        • GSK Investigational Site
      • Nowy Sącz, Polen, 33-300
        • GSK Investigational Site
      • Poznan, Polen, 60-569
        • GSK Investigational Site
      • Warsaw, Polen, 02-781
        • GSK Investigational Site
      • Moscow, Rusland, 125284
        • GSK Investigational Site
      • Nizhny Novgorod, Rusland, 603126
        • GSK Investigational Site
      • Novosibirsk, Rusland, 630087
        • GSK Investigational Site
      • Saint Petersburg, Rusland, 191024
        • GSK Investigational Site
      • Saint Petersburg, Rusland, 197 089
        • GSK Investigational Site
      • Samara, Rusland, 443021
        • GSK Investigational Site
      • Saratov, Rusland, 410028
        • GSK Investigational Site
      • Ufa, Rusland, 450083
        • GSK Investigational Site
      • Barcelona, Spanje, 08035
        • GSK Investigational Site
      • Barcelona, Spanje, 08916
        • GSK Investigational Site
      • Cáceres, Spanje, 10003
        • GSK Investigational Site
      • Gijón, Spanje, 33394
        • GSK Investigational Site
      • L'Hospitalet de Llobrega, Spanje, 08908
        • GSK Investigational Site
      • MOstoles Madrid, Spanje, 28933
        • GSK Investigational Site
      • Madrid, Spanje, 28007
        • GSK Investigational Site
      • Madrid, Spanje, 31008
        • GSK Investigational Site
      • Murcia, Spanje, 30008
        • GSK Investigational Site
      • PamplonaNavarra, Spanje, 31008
        • GSK Investigational Site
      • Pozuelo de AlarcOn Madr, Spanje, 28223
        • GSK Investigational Site
      • Salamanca, Spanje, 37007
        • GSK Investigational Site
      • Brno, Tsjechië, 625 00
        • GSK Investigational Site
      • Hradec Králové, Tsjechië, 500 05
        • GSK Investigational Site
      • Ostrava, Tsjechië, 708 52
        • GSK Investigational Site
      • Prague, Tsjechië, 128 08
        • GSK Investigational Site
      • Bournemouth, Verenigd Koninkrijk, BH7 7DW
        • GSK Investigational Site
      • Cardiff, Verenigd Koninkrijk, CF14 4XW
        • GSK Investigational Site
      • Dundee, Verenigd Koninkrijk, DD1 9SY
        • GSK Investigational Site
      • Leicester, Verenigd Koninkrijk, LE1 5WW
        • GSK Investigational Site
      • London, Verenigd Koninkrijk, W12 0NN
        • GSK Investigational Site
      • Stoke-on-Trent, Verenigd Koninkrijk, ST4 6QG
        • GSK Investigational Site
      • Sutton, Verenigd Koninkrijk, SM2 5PT
        • GSK Investigational Site
    • Arizona
      • Yuma, Arizona, Verenigde Staten, 85364
        • GSK Investigational Site
    • Kansas
      • Mission, Kansas, Verenigde Staten, 66205-2005
        • GSK Investigational Site
    • North Carolina
      • Denver, North Carolina, Verenigde Staten, 80128
        • GSK Investigational Site
    • Ohio
      • Blue Ash, Ohio, Verenigde Staten, 45242-5665
        • GSK Investigational Site
    • Texas
      • Tyler, Texas, Verenigde Staten, 75702
        • GSK Investigational Site
    • Virginia
      • Roanoke, Virginia, Verenigde Staten, 24014
        • GSK Investigational Site
      • Pusan, Zuid -Korea, 49241
        • GSK Investigational Site
      • Seongnam-si Gyeonggi-do, Zuid -Korea, 13620
        • GSK Investigational Site
      • Seoul, Zuid -Korea, 06351
        • GSK Investigational Site
      • Seoul, Zuid -Korea, 06591
        • GSK Investigational Site
      • Ulsan, Zuid -Korea, 44033
        • GSK Investigational Site

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

18 jaar en ouder (Volwassen, Oudere volwassene)

Accepteert gezonde vrijwilligers

Nee

Geslachten die in aanmerking komen voor studie

Allemaal

Beschrijving

Inclusion Criteria:

  • Confirmed diagnosis of multiple myeloma as defined by the International Myeloma Working Group (IMWG) criteria.

  • Previously treated with at least 1 prior line of multiple myeloma (MM) therapy, and must have documented disease progression during or after their most recent therapy.

  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2.

  • Must have at least 1 aspect of measurable disease, defined as one of the following;

    1. Urine M-protein excretion >=200 mg per 24-hour, or
    2. Serum M-protein concentration >=0.5 grams per deciliter (g/dL), or
    3. Serum free light chain (FLC) assay: involved FLC level >=10 mg per dL (>=100 mg per liter) and an abnormal serum free light chain ratio (<0.26 or >1.65).
  • All prior treatment-related toxicities (defined by National Cancer Institute Common Toxicity Criteria for Adverse Events [NCI-CTCAE] version 5.0) must be <=Grade 1 at the time of enrollment, except for alopecia.

  • Adequate organ function

Exclusion Criteria:

  • Intolerant to daratumumab.
  • Refractory to daratumumab or any other anti-CD38 therapy (defined as progressive disease during treatment with anti-CD38 therapy, or within 60 days of completing that treatment).
  • Intolerant to bortezomib, or refractory to bortezomib (defined as progressive disease during treatment with a bortezomib-containing regimen of 1.3 mg/m^2 twice weekly, or within 60 days of completing that treatment). Note: participants with progressive disease during treatment with a weekly bortezomib regimen are allowed.
  • Ongoing Grade 2 or higher peripheral neuropathy or neuropathic pain.
  • Prior treatment with anti-B-cell maturation antigen (anti-BCMA) therapy.
  • Prior allogenic stem cell transplant.
  • Any serious and/or unstable pre-existing medical, psychiatric disorder or other conditions, including renal, liver, cardiovascular, or certain prior malignancies.
  • Corneal epithelial disease.

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Primair doel: Behandeling
  • Toewijzing: Gerandomiseerd
  • Interventioneel model: Parallelle opdracht
  • Masker: Geen (open label)

Wapens en interventies

Deelnemersgroep / Arm
Interventie / Behandeling
Experimenteel: Belantamab mafodotin en Bortezomib plus Dexamethason (Arm A)

Humanized anti-B-cell maturation antigen (BCMA) antibody/drug conjugate

Proteasome Inhibitor

Synthetic glucocorticoid with anti-tumor activity

Actieve vergelijker: Daratumumab en Bortezomib plus Dexamethason (arm B)

Proteasome Inhibitor

Synthetic glucocorticoid with anti-tumor activity

Anti-cluster of differentiation 38 [CD-38] monoclonal antibody

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Progression-free Survival (PFS)
Tijdsspanne: Up to approximately 41 months

PFS is defined as time from randomization until earliest date of disease progression (PD), determined by Independent Review Committee (IRC), according to the International Myeloma Working Group (IMWG) Response Criteria, or death due to any cause. PD= increase of >=25% from lowest value in >=1 of following (serum M-protein [absolute increase >=0.5 grams per deciliter {g/dL}]; serum M-protein increase >=1g/dL [when lowest M-protein >=5g/dL]; urine M-protein [absolute increase >=200 milligrams per 24 hours {mg/24h}]; participants without measurable serum & urine M-protein levels, difference between involved & uninvolved serum free light chains (sFLC) levels [absolute increase >10mg/dL]; appearance of new lesion,>=50% increase from nadir in Sum of the products of the maximal perpendicular diameters of measured lesions (SPD) of >1 lesion, or >=50% increase in longest diameter of previous lesion >1 centimeter (cm) in short axis.

Up to approximately 41 months

Secundaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Aantal deelnemers met abnormale oogbevindingen bij oogonderzoek
Tijdsspanne: Tot 73 maanden
Tot 73 maanden
Complete Response Rate (CRR)
Tijdsspanne: Up to 73 months

CRR is defined as percentage of participants with a confirmed complete response or better.

Up to 73 months
Overall Response Rate (ORR)
Tijdsspanne: Up to 73 months

ORR is defined as percentage of participants with a confirmed partial response or better.

Up to 73 months
Clinical Benefit Rate (CBR)
Tijdsspanne: Up to 73 months

CBR is defined as percentage of participants with a confirmed minimal response (MR) or better

Up to 73 months
Duration of Response (DoR)
Tijdsspanne: Up to 73 months

DOR is defined as time from first documented evidence of partial response or better until first documented progression or death, whichever occurs first.

Up to 73 months
Time to Response (TTR)
Tijdsspanne: Up to 73 months

TTR is defined as time from the date of randomization and the first documented evidence of response (PR or better) among participants who achieve partial response or better.

Up to 73 months
Time to Progression (TTP)
Tijdsspanne: Up to 73 months

TTP is defined as time from the date of randomization until the earliest date of documented date of disease progression or death, whichever occurs first.

Up to 73 months
Overall Survival (OS)
Tijdsspanne: Up to 73 months

OS is defined as time from the date of randomization until the date of death due to any cause.

Up to 73 months
Progression-free Survival on Subsequent Line of Therapy (PFS2)
Tijdsspanne: Up to 73 months

Progression-free survival on subsequent line of therapy is defined as time from randomization to disease progression after initiation of new anti-myeloma therapy or death from any cause, whichever occurs first. If disease progression after new antimyeloma therapy cannot be measured, a PFS event is defined as the date of discontinuation of new anti-myeloma therapy, or death from any cause, whichever is earlier.

Up to 73 months
Minimal Residual Disease (MRD) Negativity Rate
Tijdsspanne: Up to 73 months

Minimal Residual Disease (MRD) negativity rate is defined as the percentage of participants who are MRD negative status by next generation sequencing (NGS).

Up to 73 months
Number of Participants With Adverse Events (AEs)
Tijdsspanne: Up to 73 months

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment.

Up to 73 months
Number of Participants With Clinically Significant Changes in Hematology Parameters
Tijdsspanne: Up to 73 months

Blood samples will be collected for the analysis of hematology parameters.

Up to 73 months
Number of Participants With Clinically Significant Changes in Clinical Chemistry
Tijdsspanne: Up to 73 months

Blood samples will be collected for the analysis of clinical chemistry parameters.

Up to 73 months
Number of Participants With Clinically Significant Changes in Urine Dipstick
Tijdsspanne: Up to 73 months

Urine samples will be collected for the urine dipstick analysis.

Up to 73 months
Plasma Concentrations of Belantamab Mafodotin (Total Antibody) at Indicated Time Points
Tijdsspanne: Up to 73 months

Blood samples will be collected for PK analysis of belantamab mafodotin.

Up to 73 months
Plasma Concentrations of Belantamab Mafodotin (ADC) at Indicated Time Points
Tijdsspanne: Up to 73 months

Blood samples will be collected for PK analysis of belantamab mafodotin.

Up to 73 months
Plasma Concentrations of Monomethyl Auristatin-F With a Cysteine Linker (Cys-mcMMAF) at Indicated Time Points
Tijdsspanne: Up to 73 months

Blood samples will be collected for PK analysis of belantamab mafodotin.

Up to 73 months
Number of Participants With Positive Anti-drug Antibodies (ADAs) Against Belantamab Mafodotin
Tijdsspanne: Up to 73 months

Serum samples collected for the analysis of the presence of ADAs using validated immunoassays. All samples will be tested in screening assay, and positive samples will be further characterized for antibody titers.

Up to 73 months
Titers of ADAs Against Belantamab Mafodotin
Tijdsspanne: Up to 73 months

Serum samples collected for the analysis of the presence of ADAs using validated immunoassays. All samples will be to be further tested in screening assay, and positive samples will be further to be characterized for antibody titers.

Up to 73 months
Number of Participants With Maximum Post-baseline Change From Baseline in Individual Items of Patient-Reported Outcome Version of the Common Term Criteria for Adverse Events (PRO-CTCAE)
Tijdsspanne: Up to 73 months

The PRO-CTCAE is a patient-reported outcome measure developed to evaluate symptomatic toxicity in participants on cancer clinical trials. The PRO-CTCAE includes an item library of 124 items representing 78 symptomatic toxicities drawn from the CTCAE.

Up to 73 months
Change From Baseline in Health Related Quality of Life (HRQoL) as Measured by EuropeanOrganization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30)
Tijdsspanne: Up to 73 months

The EORTC QLQ-C30 includes 30-items with single and multi-item scales. These included five functional scales (physical functioning [PF], role functioning [RF], cognitive functioning [CF], emotional functioning [EF] and social functioning [SF]), three symptom scales (fatigue, pain and nausea/vomiting [N/V]), a global health status (GHS)/ Quality-of-Life (QoL) scale, and six single items (constipation, diarrhoea, insomnia, dyspnoea, appetite loss [AL] and financial difficulties [FD]). Response options are 1 to 4. Scores were averaged and transformed to 0 to 100, a high score for functional scales/ GHS/QoL represent better functioning ability or health-related quality-of-life (HRQoL), whereas a high score for symptom scales/ single items represent significant symptomatology. Baseline was defined as latest pre-dose assessment (Day 1) with a non-missing value, including unscheduled visits. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value.

Up to 73 months
Change From Baseline in HRQoL as Measured by EORTC IL52
Tijdsspanne: Up to 73 months

The EORTC Quality of Life Questionnaire 20-item Multiple Myeloma module (QLQMY20) is a supplement to the QLQ-C30 instrument used in participants with multiple myeloma. For the EORTC IL52, disease symptoms domain of the QLQ-MY20 will be used for bone aches or pain, back pain, hip pain, arm or shoulder pain, chest pain, and pain increasing with activity. The individual component scores in the disease symptom domain are averaged and transformed linearly to a score ranging from 0 to100. A high score for disease symptoms represents a high level of symptomatology or problems. A high score represents a high/healthy level of functioning.

Up to 73 months

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Sponsor

Onderzoekers

  • Studie directeur: GSK Clinical Trials, GlaxoSmithKline

Publicaties en nuttige links

De persoon die verantwoordelijk is voor het invoeren van informatie over het onderzoek stelt deze publicaties vrijwillig ter beschikking. Dit kan gaan over alles wat met het onderzoek te maken heeft.

Algemene publicaties

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Werkelijk)

7 mei 2020

Primaire voltooiing (Werkelijk)

2 oktober 2023

Studie voltooiing (Geschat)

8 oktober 2029

Studieregistratiedata

Eerst ingediend

27 januari 2020

Eerst ingediend dat voldeed aan de QC-criteria

27 januari 2020

Eerst geplaatst (Werkelijk)

29 januari 2020

Updates van studierecords

Laatste update geplaatst (Werkelijk)

13 november 2026

Laatste update ingediend die voldeed aan QC-criteria

29 oktober 2026

Laatst geverifieerd

1 oktober 2026

Meer informatie

Termen gerelateerd aan deze studie

Plan Individuele Deelnemersgegevens (IPD)

Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?

NEE

Beschrijving IPD-plan

GSK will assess requests from qualified researchers for anonymized individual patient-level data and related study documents. Data sharing is subject to certain criteria, conditions, and exceptions. For further information, refer to https://www.gsk-studyregister.com/About_GSK_Patient_Level_Data_Sharing_Final_13July2023.pdf.

Informatie over medicijnen en apparaten, studiedocumenten

Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel

Ja

Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct

Nee

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Abonneren